Skip to main navigation

Top

Skip to main content

About Us

About Us
Rare Diseases

Rare Defined Diseases
Pipeline

Pipeline
Our Medicines

Our Medicines
Patients & Partners

Patients & Partners
Investors

Investors
Inside Agios

Inside Agios

Publications

Investors Overview
News & Events
Stock Information
Corporate Governance
Financials
IR Resources

Year

Jun 14, 2025

Patient-reported vaso-occlusive events, their associated pain severity, and impact of sickle cell disease on fatigue and quality of life: A real-world survey in the United States

Source

EHA 2025

Jun 14, 2025

PIEZO1 gain-of-function drives glycolytic imbalance in late-stage erythropoiesis: The potential of mitapivat therapy in dehydrated hereditary stomatocytosis

Source

EHA 2025

Jun 14, 2025

Ex-vivo activation of pyruvate kinase by tebapivat reduces sickling and red blood cell adhesion in sickle cell disease

Source

EHA 2025

Jun 14, 2025

ENERGIZE-T/ENERGIZE: Roxyscan assesses pyruvate kinase activator’s effect on oxidative stress sensitivity in β-thalassemia patients

Source

EHA 2025

Jun 14, 2025

Red blood cell age distribution and metabolic features in hereditary spherocytosis, hereditary xerocytosis and congenital dyserythropoietic anemia – baseline results of exploratory analysis from the SATISFY study

Source

EHA 2025

Jun 13, 2025

Impact of non-transfusion-dependent thalassemia on adult patients’ health-related quality of life and work productivity: A multi-region real-world survey

Source

EHA 2025

Jun 12, 2025

Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: Results from a phase 2, open-label study

Source

EHA 2025

Jun 12, 2025

Efficacy and safety of mitapivat in pediatric patients with pyruvate kinase deficiency who are regularly transfused: Results from the phase 3 randomized global placebo-controlled ACTIVATE-KidsT trial

Source

EHA 2025

Jun 12, 2025

Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: Results from a phase 2, open-label study

Source

EHA 2025

Jun 12, 2025

SATISFY: Mitapivat in adults with erythrocyte membranopathies and congenital dyserythropoietic anemia type II: A EuroBloodNet, multicenter, single-arm, phase 2 study

Source

EHA 2025

For details on our former oncology programs, visit https://www.servier.us/.

Latest Earnings Call View Replay
Latest Form 10-K View PDF
Email Alerts Sign Up
Corporate Responsibility View PDF

Connect with us on LinkedIn or follow us on X.

Connect on LinkedIn

Follow us on X

Contact
About Us
Partner Opportunities
Careers

Agios Pharmaceuticals, Inc. © 2026

All right reserved.

Cookies Preferences
Copyright Info
Compliance
Sitemap
Privacy Notice
Terms of Use